Close Menu

Myriad

Although the logistics still need to be worked out, the partners hope to streamline oncologists' experience ordering tests that can inform patient care.

The new service, slated for launch in the second half of 2021, will allow Myriad to expand its cancer tumor profiling services.

Total revenues for the period were $154.6 million, down from $195.1 million but beating the consensus Wall Street estimate.

Among firms presenting on the first day, 10x Genomics revealed it is developing a new high-throughput Chromium instrument, and Guardant plans to launch a comprehensive tissue sequencing assay.

The firm also provided preliminary revenues of $950 million for Q4 and reinstated guidance of $3.79 billion to $3.88 billion for 2021.

The changes follow a strategic review and are part of the company's previously announced plans for growing its revenues and reducing costs. 

Despite the havoc wreaked by the COVID-19 pandemic on the economy, several companies in the index saw their shares rise by triple-digit percentages last year.

The consortium aims to harmonize the use of homologous recombination deficiency as a biomarker to guide certain treatment types in cancer patients.

The index underperformed the Dow Jones, the Nasdaq, and the Nasdaq Biotechnology Index, which all swung up on positive coronavirus vaccine news.

Pages

The FDA and CDC call for a pause in administering Johnson & Johnson's SARS-CoV-2 vaccine while reports of rare blood clots are looked into, reports the Wall Street Journal.

CNN reports that two new studies suggest the B.1.1.7 SARS-CoV-2 variant may be more transmissible, but may not lead to more severe disease.

According to the Associated Press, a Swiss program aims to shepherd long-term science projects and diplomacy.

In PNAS this week: analysis of pathway affecting acute kidney injury, parental-specific allelic expression in horse placenta, and more.